ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,633 | -22.7% | 158 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $7,289 | +15.0% | 158 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $6,336 | +92.6% | 158 | +122.5% | 0.00% | +50.0% |
| Q4 2022 | $3,289 | +9.6% | 71 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | -25.0% | 71 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $4,000 | +33.3% | 71 | +91.9% | 0.00% | 0.0% |
| Q4 2021 | $3,000 | 0.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $3,000 | -25.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | 0.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $4,000 | -33.3% | 37 | -22.9% | 0.00% | -50.0% |
| Q4 2020 | $6,000 | +50.0% | 48 | -43.5% | 0.00% | +33.3% |
| Q3 2019 | $4,000 | -33.3% | 85 | -9.6% | 0.00% | -25.0% |
| Q2 2019 | $6,000 | -14.3% | 94 | 0.0% | 0.00% | -20.0% |
| Q1 2019 | $7,000 | 0.0% | 94 | -3.1% | 0.01% | +66.7% |
| Q3 2018 | $7,000 | – | 97 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |